MedWatch·Industry news·Regulatory & legal·4mo agoDemant CEO warns about new EU AI regulationsEU AI regulation could slow the development pipeline and market availability of AI-powered hearing devices, with downstream effects on the full audiology supply chain.＋Save
Hearing Tracker·Industry news·Business & finance·4mo agoDemant Names Bassel Rifai President of Hearing AidsLeadership transitions at top-five hearing aid manufacturers can influence product strategy, partnership priorities, and market direction for the broader audiology field.＋Save
MedWatch·Financial report·Business & finance·5mo agoDanske Bank sees promising outlook for Demant after strong Q1Investor confidence in Demant signals continued R&D and commercial momentum for Oticon products, which may shape future device availability and competition in the hearing aid market.＋Save
MedWatch·Financial report·Business & finance·5mo agoDemant delivers strong start to the year on relaunch momentumDemant's relaunch-driven momentum suggests the company is prioritizing portfolio refresh over entirely new platforms, which may affect the pace of clinically meaningful innovation in the near term.＋Save
MedWatch·Industry news·Business & finance·5mo agoJyske Bank: Demant’s strong start points to high-end resultsPositive analyst coverage can reflect and reinforce investor confidence in Demant's portfolio strategy, indirectly signaling stability for the audiologists and dispensers who rely on their products.＋Save
MedWatch·Industry news·Business & finance·5mo agoDemant CEO teases new launches: "Our platform is very strong"Anticipated Demant product launches could shift competitive dynamics in the premium hearing aid segment and affect dispensing choices for clinicians.＋Save
MedWatch·Financial report·Business & finance·5mo agoDemant maintains guidance, sees lower-end outcome as "less likely"Demant's confidence in its growth trajectory signals continued investment capacity in hearing technology R&D and market expansion.＋Save
Hearing Tracker·Financial report·Business & finance·5mo agoDemant Reports 6% Organic Growth in Q1 2026, Driven by Strong Oticon Zeal LaunchDemant's growth driven by the Oticon Zeal launch signals continued market momentum in premium hearing aids, which may influence product availability, pricing competition, and clinic purchasing decisions.＋Save
MedWatch·Financial report·Business & finance·5mo agoDanske Bank sees potential focus on Demant’s miniature product launch and GN’s sale to Amplifon in interim reportA potential GN–Amplifon deal and Demant's product pipeline are market-shaping events that could alter competitive dynamics, pricing, and product availability across audiology clinics globally.＋Save
MedWatch·Industry news·Hearing aids·5mo agoDemant launches Oticon Zeal through retail channels in the USInclusion of a new hearing aid in the VA contract significantly expands its reach to one of the largest publicly funded hearing healthcare populations in the US.＋Save
Hearing Tracker·Financial report·Business & finance·8mo agoDemant Reports 2025 Revenue Growth but Lower Profits, Forcing Cost Cutting ProgramCost-cutting at a major hearing aid manufacturer could eventually affect product development timelines, workforce, and supply partnerships across the audiology industry.＋Save
Hearing Tracker·Industry news·Business & finance·9mo agoDemant Sells EPOS to ACCO Brands to Focus Fully on Hearing HealthcareDemant's divestiture of a non-core audio brand signals a sharpened industry focus on hearing healthcare, which could accelerate product investment and affect competitive dynamics for clinics that carry Demant-affiliated brands.＋Save
